Switching from ibrutinib to venetoclax in chronic lymphocytic leukemia: a management protocol based on clinical cases avoiding rapid disease progression

Autor: Erik de Cabo López, Ma. Jesús Vidal-Manceñido, Josefina Galende del Canto, Carmen Aguilera Sanz, Marta Megido Lahera, Alicia Smucler Simonovich, Sheila Bodelón Gago, Carlos A. Cuenca Aprell

Publikováno v: Revista Sangre (ENG). 41

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f95905e96b17d0d2a91318311bf64939
https://doi.org/10.24875/sangree.22000003

Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)

Autor: Cristina Loriente, Inmaculada Pérez, Montserrat López Rubio, Ana Cristina Godoy, María del Carmen Losada Castillo, Carolina Cuellar-García, Eduardo Ríos, Lucrecia Yáñez, Maria Dolores Garcia Malo, Ana Lario, Pau Abrisqueta, Julio Delgado, Mª José Berruezo, Alicia Smucler Simonovich, Alicia Rodríguez, Rafael Ramos, Miguel Villanueva, José Mª Arguiñano Pérez, Daniel Acha, Margarita Fernández de la Mata, Isidro Jarque, Javier Loscertales, Jose Luis Bello, Santiago Osorio, Paloma Martin, Angel Ramirez Payer, Macarena Ortiz, Ernesto Pérez Persona, Rubén Fernández Álvarez, Aima Lancharro Anchel, Jose Angel Hernandez-Rivas, Miguel Fernández-Zarzoso, Ana Célia Carneiro Oliveira, Patricia Baltasar, Angeles Medina, Mª Jesús Vidal Manceñido, Alexia Suarez, Ricardo García Muñoz, María José Terol, Fernando De Marco

Publikováno v: Clinical lymphoma, myeloma & leukemia
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
r-FISABIO. Repositorio Institucional de Producción Científica
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Dipòsit Digital de la UB
Universidad de Barcelona

Ibrutinib demonstrated robust efficacy, regardless of high-risk features, in previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL). The IBRORS-CLL study supports the effectiveness and the manageable safety profile of single-a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46c4f2a1bd607572095c4a75307637b0
https://pubmed.ncbi.nlm.nih.gov/34511320

Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study

Autor: Alicia Smucler Simonovich, Eduardo Ríos Herranz, José A. Márquez, Sandra Iraheta, Angel Ramirez Payer, Macarena Ortiz, Javier Loscertales, Ernesto Pérez Persona, Jose Manuel Puerta, María José Terol, Javier de la Serna, Patricia Baltasar, José A. García-Marco, Begoña Muiña, Tomas García, Rafael Andreu, Fatima De la Cruz, Ana Muntañola Prat, Gonzalo Caballero, Diana Moreno, Marcos González Díaz, Ruben Fernandez, Juan Marquet Palomanes, Laura Magnano, Carol Moreno, María Angeles Andreu, Jose M Arguiñano, Ana Ruiz-Zorrilla, Santiago Osorio, Lucrecia Yáñez, Christelle Ferra, Manuel Pérez-Encinas

Publikováno v: Blood. 138:1561-1561

Introduction: The BCL-2 inhibitor venetoclax (Ven) has been approved on monotherapy or combined with rituximab in relapsed/refractory CLL patients (pts) and combined with obinutuzumab in previously untreated CLL pts. However, evidence from clinical t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::731ff73828e032141aa4a86575105c96
https://doi.org/10.1182/blood-2021-147685

Estudio de incidencia de las neoplasias hematopoyéticas en Castilla y León

Autor: José Antonio Rodríguez-García, Alberto Cantalapiedra, Carlos Aguilar, Lourdes Vázquez, M J Calmuntia, María José Cebeira, José María Quiroga Alonso, Magdalena Sierra, Eva Díez, Alicia Smucler, Rosa Cantalejo, Dulce Nombre Guerola, José Antonio Gracia, Alejandro Martín, Fernando Ramos, Silvia Fernández, Maria J. Rodriguez, Beatriz Cuevas

Publikováno v: Medicina Clínica. 144:491-500

Resumen Fundamento y objetivo Conocer la incidencia de las neoplasias hematopoyeticas (NH) en Castilla y Leon, una region de 2,5 millones de habitantes, y su distribucion en funcion de la edad, el sexo y el subtipo histologico. Pacientes y metodo Se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::03504abca359e84e3c63f1fdee724a6c
https://doi.org/10.1016/j.medcli.2014.03.037

[Incidence of haematological neoplasms in Castilla y León, Spain]

Autor: Magdalena Sierra, María José Cebeira, M J Calmuntia, Alicia Smucler, Alejandro Martín, Fernando Ramos, José María Quiroga Alonso, Beatriz Cuevas, Silvia Fernández, Maria J. Rodriguez, José Antonio Rodríguez-García, Eva Díez, José Antonio Gracia, Alberto Cantalapiedra, Rosa Cantalejo, Carlos Aguilar, Dulce Nombre Guerola, Lourdes Vázquez

Publikováno v: Medicina clinica. 144(11)

Background and objective We aimed to assess the incidence of haematological neoplasms (HNs) in Castilla y Leon (2.5 million inhabitants) and its distribution by age, gender and histological type. Patients and method The epidemiological profile based

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32e98b7e41f37dc68da5effb0da2b91b
https://pubmed.ncbi.nlm.nih.gov/25015251